中国儿童甲状腺结节及分化型甲状腺癌专家共识

2020-10-30 国家儿童医学中心(北京) 中华实用儿科临床杂志.2020.35(10):1521-1530.

与成人相比,儿童甲状腺肿瘤在生物学特性、临床特点及长期预后方面存在明显差异。更为重要的是,研究表明针对成人患者的治疗措施并不能完全适用于儿童。对于儿童甲状腺肿瘤患者,治疗不足和治疗过度均会对其造成更长

中文标题:

中国儿童甲状腺结节及分化型甲状腺癌专家共识

发布日期:

2020-10-30

简要介绍:

与成人相比,儿童甲状腺肿瘤在生物学特性、临床特点及长期预后方面存在明显差异。更为重要的是,研究表明针对成人患者的治疗措施并不能完全适用于儿童。对于儿童甲状腺肿瘤患者,治疗不足和治疗过度均会对其造成更长期的伤害。在2015年美国发布的《儿童甲状腺结节和分化型甲状腺癌管理指南》中,明确指出儿童不是成人的缩小版。然而,国内现有甲状腺结节和甲状腺癌的指南和专家共识均是针对成人患者。为提高我国对儿童甲状腺肿瘤的诊治水平,促进诊疗规范化,制定本共识。共识内容包含儿童甲状腺结节和分化型甲状腺癌的临床特点、系统评估、外科治疗、131I治疗、内分泌治疗、肿瘤分期、术后危险度分级和随访等相关的40条推荐意见,并对这些意见的推荐强度进行了分级。

 

下载附件:

(因为版权问题,不支持下载)

评论区 (24)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2125506, encodeId=24f021255062b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:26:11 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2125501, encodeId=19322125501bb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:22:56 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1066158, encodeId=e7dc1066158bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77895683914, createdName=ms1000001308978381, createdTime=Tue Nov 02 10:47:21 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066157, encodeId=e342106615ea0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77895683914, createdName=ms1000001308978381, createdTime=Tue Nov 02 10:47:03 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060165, encodeId=b5db10601659c, content=还是和成人很不一样, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201013/0312efcacd004bd4a3d491b5021a02fc/157f8e78efb7472daba43996cc0eda28.jpg, createdBy=03b75425648, createdName=shuwengweng, createdTime=Wed Oct 13 16:06:01 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2023-04-12 1471d48dm72暂无昵称 来自安徽省

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2125506, encodeId=24f021255062b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:26:11 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2125501, encodeId=19322125501bb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:22:56 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1066158, encodeId=e7dc1066158bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77895683914, createdName=ms1000001308978381, createdTime=Tue Nov 02 10:47:21 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066157, encodeId=e342106615ea0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77895683914, createdName=ms1000001308978381, createdTime=Tue Nov 02 10:47:03 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060165, encodeId=b5db10601659c, content=还是和成人很不一样, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201013/0312efcacd004bd4a3d491b5021a02fc/157f8e78efb7472daba43996cc0eda28.jpg, createdBy=03b75425648, createdName=shuwengweng, createdTime=Wed Oct 13 16:06:01 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2023-04-12 1471d48dm72暂无昵称 来自安徽省

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2125506, encodeId=24f021255062b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:26:11 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2125501, encodeId=19322125501bb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:22:56 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1066158, encodeId=e7dc1066158bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77895683914, createdName=ms1000001308978381, createdTime=Tue Nov 02 10:47:21 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066157, encodeId=e342106615ea0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77895683914, createdName=ms1000001308978381, createdTime=Tue Nov 02 10:47:03 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060165, encodeId=b5db10601659c, content=还是和成人很不一样, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201013/0312efcacd004bd4a3d491b5021a02fc/157f8e78efb7472daba43996cc0eda28.jpg, createdBy=03b75425648, createdName=shuwengweng, createdTime=Wed Oct 13 16:06:01 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-11-02 ms1000001308978381

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2125506, encodeId=24f021255062b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:26:11 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2125501, encodeId=19322125501bb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:22:56 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1066158, encodeId=e7dc1066158bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77895683914, createdName=ms1000001308978381, createdTime=Tue Nov 02 10:47:21 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066157, encodeId=e342106615ea0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77895683914, createdName=ms1000001308978381, createdTime=Tue Nov 02 10:47:03 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060165, encodeId=b5db10601659c, content=还是和成人很不一样, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201013/0312efcacd004bd4a3d491b5021a02fc/157f8e78efb7472daba43996cc0eda28.jpg, createdBy=03b75425648, createdName=shuwengweng, createdTime=Wed Oct 13 16:06:01 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-11-02 ms1000001308978381

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2125506, encodeId=24f021255062b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:26:11 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2125501, encodeId=19322125501bb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:22:56 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1066158, encodeId=e7dc1066158bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77895683914, createdName=ms1000001308978381, createdTime=Tue Nov 02 10:47:21 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066157, encodeId=e342106615ea0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77895683914, createdName=ms1000001308978381, createdTime=Tue Nov 02 10:47:03 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060165, encodeId=b5db10601659c, content=还是和成人很不一样, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201013/0312efcacd004bd4a3d491b5021a02fc/157f8e78efb7472daba43996cc0eda28.jpg, createdBy=03b75425648, createdName=shuwengweng, createdTime=Wed Oct 13 16:06:01 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 shuwengweng

    还是和成人很不一样

    0

拓展阅读

2016 AACE/ACE/AME指南:甲状腺结节的诊断和管理

美国临床内分泌医师学会(AACE,American Association of Clinical Endocrinologists) · 2016-05-16

2018 KSThR共识声明:甲状腺结节乙醇消融治疗

韩国甲状腺放射学会(KSThR,Korean Society of Thyroid Radiology) · 2019-03-20

2020年欧洲甲状腺协会在良性甲状腺结节中使用图像引导消融的临床实践指南

欧洲甲状腺协会(ETA,European Thyroid Association) · 2020-09-01

2020甲状腺结节超声恶性危险分层中国指南:C-TIRADS

中华医学会超声医学分会 · 2021-03-30